Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 04, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces Third Quarter 2025 Financial Results and Provides Business Update

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare...
August 18, 2025 04:00 ET | Source: AKAMPION

BellaSeno Establishes High-Profile Clinical Advisory Board

Leading international experts to support clinical development of BellaSeno´s pioneering resorbable breast implantsPivotal clinical trial to be initiated shortly Leipzig, Germany / Brisbane,...
June 24, 2025 06:30 ET | Source: Longeveron

Longeveron® Announces Completion of Enrollment of Pivotal Phase 2b Clinical Trial Evaluating Laromestrocel as a Treatment for Hypoplastic Left Heart Syndrome (HLHS)

Longeveron® completes enrollment of pivotal Phase 2b clinical trial evaluating laromestrocel as a treatment for Hypoplastic Left Heart Syndrome (HLHS).
May 20, 2025 09:15 ET | Source: Longeveron

Longeveron® to Attend BIO International Convention 2025

Longeveron to host Alzheimer's disease program partnering meetings at BIO 2025 conference June 16-19. Positive Phase 2a data published in Nature Medicine.
May 08, 2025 16:05 ET | Source: Longeveron

Longeveron® Announces First Quarter 2025 Financial Results and Provides Business Update

Longeveron announces Q1 2025 financial results & provides business update. Pivotal Phase 2 clinical trial achieves 95% enrollment. Expected full enroll Q2.
March 20, 2025 09:00 ET | Source: Longeveron

Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease

Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.
February 15, 2022 09:00 ET | Source: Neurocentria, Inc

Neurocentria Obtains FDA Approval to Conduct Pivotal Phase IIb/III Clinical Trial for Testing Safety and Efficacy of Drug Candidate NRCT-101SR in Adults With ADHD

WALNUT CREEK, N.C., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Neurocentria Inc., a privately held late-stage biotechnology company developing novel therapies for Alzheimer's disease, Attention Deficit...